Therapeutical use of probiotic formulations in clinical practice

Clinical Nutrition

Volumn 29, Issue 6, 2010, Pages 701-725

  Iannitti, T ^a   Palmieri, B ^b  

^a GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Disease; Dysbiosis; Microbiota; Probiotic

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; CLARITHROMYCIN; CLINDAMYCIN; FRUCTOSE OLIGOSACCHARIDE; GALACTOSE OLIGOSACCHARIDE; LEBENIN; LP 299V; MESALAZINE; METRONIDAZOLE; NEOMYCIN; NITAZOXANIDE; PLACEBO; PREBIOTIC AGENT; PREDNISOLONE; PREDNISONE; PRESCRIPT ASSIST; PROBIOTIC AGENT; PROSYMBIOFLOR; PROTON PUMP INHIBITOR; RIFAXIMIN; SULFADIAZINE SILVER; SYMBIOFLOR 2; SYNBIOTIC AGENT; THALIDOMIDE; TINIDAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VSL3;

ABSENCE OF SIDE EFFECTS; ALCOHOL LIVER CIRRHOSIS; ALLERGIC DISEASE; ATOPIC DERMATITIS; BACILLUS COAGULANS; BACTEREMIA; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM INFANTIS; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COLON CANCER; COLON DIVERTICULOSIS; COLON TUMOR; COMBINATION CHEMOTHERAPY; CONSTIPATION; CROHN DISEASE; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; ECZEMA; EXCISION; FUNGEMIA; HELICOBACTER INFECTION; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERLIPIDEMIA; HYPOTENSION; ILEITIS; INFECTIOUS DIARRHEA; INTESTINE FLORA; INTESTINE PREPARATION; IRRITABLE COLON; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS FERMENTUM; LACTOBACILLUS JOHNSONII; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; LIVER CIRRHOSIS; MONOTHERAPY; MORNING DOSAGE; MUCOSAL IMMUNITY; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; POSTOPERATIVE INFECTION; PROPIONIBACTERIUM FREUDENREICHII SHERMANII; REVIEW; SACCHAROMYCES BOULARDII; SEPSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VAGINITIS; VOMITING; WOUND INFECTION;

ADMINISTRATION, ORAL; ANTIGENS, BACTERIAL; CROHN DISEASE; FEMALE; FOOD SAFETY; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HELICOBACTER PYLORI; HUMANS; INTESTINES; MALE; METAGENOME; OLIGOSACCHARIDES; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES;

EID: 78649849281     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2010.05.004     Document Type: Review

References (122)

1. Neish Andrew S. Microbes in gastrointestinal health and disease. Gastroenterology 2009, 136:65-80.
2. Marchesi Julian, Shanahan Fergus The normal intestinal microbiota. Curr Opin Infect Dis 2007, 20:508-513.
3. Tennyson Christina A., Friedman Gerald Microecology, obesity, and probiotics. Current opinion in Endocrinology. Diabetes Obes 2008, 15:422-427.
4. Dibaise John K., Zhang Husen, Crowell Michael D., Krajmalnik-Brown Rosa, Anton Decker G., Rittmann Bruce E. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc April 2008, 83(4):460-546.
5. Probiotics. A publication of the institute of food technologists' expert panel on food safety and nutrition. vol. 53, No. 11 November 1999.
6. Probiotics - Friendly Bacteria with a Host of Benefits. Dairy Council of California, 2000.
7. Neufeld Karen-Anne, Foster Jane A. Effects of gut microbiota on the brain: implications for psychiatry. J Psychiatry Neurosci 2009, 34(3):230-231.
8. Reinhardt Christoph, Reigstad Christopher S., Backhed Fredrik Intestinal microbiota during infancy and its implications for obesity. J Pediatr Gastroenterol Nutr March 2009, 48(No. 3).
9. C. De Simone, G. Famularo, B. Bianchi Salvadori, R. Vesely. Prospettive terapeutiche dei batteri lattici. Teoria e Applicazioni nel Dismicrobismo Intestinale. Piccin editore.
10. Round June L., Mazmanian Sarkis K. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunology May 2009, 9.
11. Preidis Geoffrey A., Versalovic James Targeting the human Microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 2009, 136:2015-2031.
12. Indu Pal Kaur, Kanwaljit Chopra, Amarpreet Saini Probiotics: potential pharmaceutical applications. Eur J Pharm Sci 2002, 15:1-9.
13. Gupta V., Garg R. Probiotics. Indian J Med Microbiol 2009, 27(3):202-209.
14. Bornet F.R., Brouns F., Tashiro Y., Duvillier V. Nutritional aspects of short-chain fructooligosaccharides: natural occurrence, chemistry, physiology and health implications. Dig Liver Dis 2002 Sep, 34(Suppl. 2):S111-S120.
15. Buddington Randal K., Williams Carol H., Chen Sui-Chi, Steven A. Witherly Dietary supplement of neosugar alters the fecal flora and decreases activities of some reductive enzymes in human subjects. Am J Clin Nutr 1996, 63:709-716.
16. Williams C.H., Witherly S.A., Buddington R.K. Influence of dietary neosugar on selected bacterial groups of the human faecal microbiota. Microb Ecol Health Dis 1994, 7:91-97.
17. Bornet Francis R.J. Undigestible sugars in food products. Am J Clin Nutr 1994, 59(Suppl.):763S-769S.
18. Hidaka Hidemasa, Tashiro Yasuhito, Eida Toshiaki Proliferation of bifidobacteria by Oligasaccharides and their Effetc on human health. Bifidobacteria Microflora 1991, 10(1):65-79.
19. Hidaka Hidemasa, Eida Toshiaki, Takizawa Toshio, Tokunaga Takahisa, Tashiro Yasuhito Effetcts of fructooligosaccharides on intestinal flora and human health. Bifidobacteria Microflora 1986, 5(1):37-50.
20. Amenta M., Cascio M.T., Di Fiore P., Venturini I. Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir fos (Bifidobacterium longum W11 + FOS Actilight). Acta Biomed 2006 Dec, 77(3):157-162.
21. Franz Zunft H.J., Hanisch C., Mueller S., Koebnick C., Blaut M., Dorè J. Sunbiotic containing Bifidobacterium animalis and inulin increases stool frequency in elderly healthy people. Asia Pac J Clin Nutr 2004, 13(Suppl.).
22. Malaguarnera M., Greco F., Barone G., Gargante M.P., Malaguarnera M., Toscano M.A. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007 Nov, 52(11):3259-3265. Epub 2007 Mar 28.
23. Katharina E., Scholz-Ahrens, Schaafsma Gertjan, GHM van den Heuvel Ellen, Schrezenmeir Jürgen Effects of prebiotics on mineral metabolism. Am J Clin Nutr 2001, 73(suppl). 459S-454S.
24. Giovanni Brandi, Monica Di Battista. I sinbiotici nella salute dell'apparato gastrointestinale. Suppl. a M.D. Medicinae Doctor, X, 23, 2003.
25. Giovanni Brandi. Bifidobatteri e FOS: azione sinbiotica per la salute. Utet Periodici, Settembre 2003.
26. Salminem Seppo J., Gueimonde Miguel, Isolauri Erika Probiotics that modify disease risk. J Nutr 2005, 135:1294-1298.
27. Kaila Kailasapathy and James Chin Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol Cell Biol 2000, 78:80-88.
28. Gibson G.-R., Roberfroid M.-B. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995, 125(6):33.
29. David Collins M., Gibson Glenn R. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 1999, 69(suppl.):1052S-1057S.
30. Snydman D.R. The safety of probiotics. Clin Infect Dis 2008 Feb 1, 46(Suppl. 2):S104-S111.
31. Wassenaar T.M., Klein G. Safety aspects and implications of regulation of probiotic bacteria in food and food supplements. J Food Prot 2008 Aug, 71(8):1734-1741.
32. Liong M.T. Safety of probiotics: translocation and infection. Nutr Rev 2008 Apr, 66(4):192-202.
33. Lammers K.M., Vergopoulos A., Babel N., Gionchetti P., Rizzello F., Morselli C., et al. Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. Inflamm Bowel Dis 2005 May, 11(5):447-454.
34. Marschan E., Kuitunen M., Kukkonen K., Poussa T., Sarnesto A., Haahtela T., et al. Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. Clin Exp Allergy 2008 Apr, 38(4):611-618. Epub 2008 Feb 11.
35. Stadlbauer V., Mookerjee R.P., Hodges S., Wright G.A., Davies N.A., Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008 Jun, 48(6):945-951. Epub 2008 Mar 25.
36. Kekkonen R.A., Kajasto E., Miettinen M., Veckman V., Korpela R., Julkunen I. Probiotic Leuconostoc mesenteroides ssp. cremoris and Streptococcus thermophilus induce IL-12 and IFN-gamma production. World J Gastroenterol 2008 Feb 28, 14(8):1192-1203.
37. Kekkonen R.A., Sysi-Aho M., Seppanen-Laakso T., Julkunen I., Vapaatalo H., Oresic M., et al. Effect of probiotic Lactobacillus rhamnosus GG intervention on global serum lipidomic profiles in healthy adults. World J Gastroenterol 2008 May 28, 14(20):3188-3194.
38. Takeda K., Suzuki T., Shimada S.I., Shida K., Nanno M., Okumura K. Interleukin-12 is involved in the enhancement of human natural killer cell activity by Lactobacillus casei Shirota. Clin Exp Immunol 2006 Oct, 146(1):109-115.
39. Ivory K., Chambers S.J., Pin C., Prieto E., Arqués J.L., Nicoletti C. Oral delivery of Lactobacillus casei Shirota modifies allergen-induced immune responses in allergic rhinitis. Clin Exp Allergy 2008 Aug, 38(8):1282-1289. Epub 2008 May 28.
40. Twetman S., Derawi B., Keller M., Ekstrand K., Yucel-Lindberg T., Stecksen-Blicks C. Short-term effect of chewing gums containing probiotic Lactobacillus reuteri on the levels of inflammatory mediators in gingival crevicular fluid. Acta Odontol Scand 2009 Feb, 67(1):19-24.
41. Valdéz J.C., Peral M.C., Rachid M., Santana M. Perdigón G. Interference of Lactobacillus plantarum with Pseudomonas aeruginosa in vitro and in infected burns: the potential use of probiotics in wound treatment. Clin Microbiol Infect 2005 Jun, 11(6):472-479.
42. Peral M.C., Martinez M.A., Valdez J.C. Bacteriotherapy with Lactobacillus plantarum in burns. Int Wound J 2009 Feb, 6(1):73-81.
43. Ji G.E. Probiotics in primary prevention of atopic dermatitis. Forum Nutr 2009, 61:117-128. Epub 2009 Apr 7.
44. Gueniche A., Knaudt B., Schuck E., Volz T., Bastien P., Martin R., et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol 2008 Dec, 159(6):1357-1363. Epub 2008 Sep 15.
45. Zuccotti G.V., Meneghin F., Raimondi C., Dilillo D., Agostoni C., Riva E., Giovannini M. Probiotics in clinical practise: an overview. J Int Med Res 2008, 36(Suppl. 1).
46. Wickens K., Black P.N., Stanley T.V., Mitchell E., Fitzharris P., Tannock G.W., et al. A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2008 Oct, 122(4):788-794. Probiotic Study Group, Epub 2008 Aug 31.
47. Abrahamsson T.R., Jakobsson T., Böttcher M.F., Fredrikson M., Jenmalm M.C., Björkstén B., et al. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2007 May, 119(5):1174-1180. Epub 2007 Mar 8.
48. Kukkonen K., Savilahti E., Haahtela T., Juntunen-Backman K., Korpela R., Poussa T., et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2007 Jan, 119(1):192-198. Epub 2006 Oct 23.
49. Falk Anders, Jeppsson Bengt The treatment of pouchitis - is there a role for probiotics?. Kuwait Med J 2004, 36(2):93-97.
50. Pronio A., Montesani C., Butteroni C., Vecchione S., Mumolo G., Vestri A., et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 2008 May, 14(5):662-668.
51. Rayes N., Seehofer D., Theruvath T., Mogl M., Langrehr J.M., Nüssler N.C., et al. Effect of enteral nutrition and synbiotics on bacterial infection rates after pylorus-preserving pancreatoduodenectomy: a randomized, double-blind trial. Ann Surg 2007 Jul, 246(1):36-41.
52. Nomura T., Tsuchiya Y., Nashimoto A., Yabusaki H., Takii Y., Nakagawa S., et al. Probiotics reduce infectious complications after pancreaticoduodenectomy. Hepatogastroenterology 2007 Apr/May, 54(75):661-663.
53. Reddy B.S., Macfie J., Gatt M., Larsen C.N., Jensen S.S., Leser T.D. Randomized clinical trial of effect of synbiotics, neomycin and mechanical bowel preparation on intestinal barrier function in patients undergoing colectomy. Br J Surg 2007 May, 94(5):546-554.
54. Van Gossum A., Dewit O., Louis E., de Hertogh G., Baert F., Fontaine F., et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis 2007 Feb, 13(2):135-142.
55. Sugawara G., Nagino M., Nishio H., Ebata T., Takagi K., Asahara T., et al. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg 2006 Nov, 244(5):706-714.
56. Woodard G.A., Encarnacion B., Downey J.R., Peraza J., Chong K., Hernandez-Boussard T., et al. Probiotics improve outcomes after Roux-en-Y gastric bypass surgery: a prospective randomized trial. J Gastrointest Surg 2009 Jul, 13(7):1198-1204. Epub 2009 Apr 18.
57. Reid G., Bruce A. Urogenital infections in women: can probiotics help?. Postgrad Med J 2003, 79:428-432.
58. Czaja C.A., Stapleton A.E., Yarova-Yarovaya Y., Stamm W.E. Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women. Infect Dis Obstet Gynecol 2007, 2007:35387.
59. Anukam K.C., Osazuwa E., Osemene G.I., Ehigiagbe F., Bruce A.W., Reid G. Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect 2006 Oct, 8(12-13):2772-2776. Epub 2006 Sep 11.
60. Martinez R.C., Franceschini S.A., Patta M.C., Quintana S.M., Gomes B.C., De Martinis E.C., Reid G. Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial. Can J Microbiol 2009 Feb, 55(2):133-138.
61. Mastromarino P., Macchia S., Meggiorini L., Trinchieri V., Mosca L., Perluigi M., et al. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin Microbiol Infect 2009 Jan, 15(1):67-74. Epub 2008 Nov 22.
62. Larsson P.G., Stray-Pedersen B., Ryttig K.R., Larsen S. Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health 2008 Jan 15, 8:3.
63. Yangco B.G., Sher G., Bardin M.C. Nitazoxanide and probiotics for the treatment of recurrent Clostridium difficile infection in a peritoneal dialysis patient. South Med J 2009 Jul, 102(7):746-747.
64. Hida M., Aiba Y., Sawamura S., Suzuki N., Satoh T., Koga Y. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996, 74(2):349-355.
65. Taki K., Takayama F., Niwa T. Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J Ren Nutr 2005 Jan, 15(1):77-80.
66. Colecchia Antonio, Sandri Lorenza, Capodicasa Simona, Vestito Amanda, Mazzella Giuseppe, Staniscia Tommaso, Roda Enrico, Festi Davide Diverticular disease of the colon: new perspectives in symptom development and treatment. World J Gastroenterol 2003 Jul, 9(7):1385-1389.
67. Tursi A., Brandimarte G., Giorgetti G.M., Elisei W., Aiello F. Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Colorectal Dis 2007 Sep, 22(9):1103-1108. Epub 2007 Mar 28.
68. Tursi A., Brandimarte G., Giorgetti G.M., Elisei W. Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. Hepatogastroenterology 2008 May/Jun, 55(84):916-920.
69. World Gastroenterology Organisation Global Guideline. Irritable bowel syndrome: a global perspective. April 20, 2009.
70. Zeng J., Li Y.Q., Zuo X.L., Zhen Y.B., Yang J., Liu C.H. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008 Oct 15, 28(8):994-1002. Epub 2008 Jul 30.
71. Colecchia A., Vestito A., La Rocca A., Pasqui F., Nikiforaki A., Festi D. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol Dietol 2006 Dec, 52(4):349-358. Symbiotic Study Group.
72. Vanderhoof J.A., Young R.J. Use of probiotics in childhood gastrointestinal disorders. J-Pediatr-Gastroenterol-Nutr 1998, 27(3):47.
73. Tsuchiya J., Barreto R., Okura R., Kawakita S., Fesce E., Marotta F. Single blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004, 5:169-174.
74. O'Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541-551.
75. Furrie E. Is Bifidobacterium a more effective probiotic therapy than Lactobacillus for patients with irritable bowel syndrome?. Nat Clin Pract Gastroenterol Hepatol 2005 Jul, 2(7):304-305.
76. Guslandi M. Probiotic agents in the treatment of irritable bowel syndrome. J Int Med Res 2007, 35:583-589.
77. Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 2009 Mar, 121(2):119-124.
78. Enck P., Zimmermann K., Menke G., Klosterhalfen S., Gastroenterol Z. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo. Z Gastroenterol 2009 Feb, 47(2):209-214. Epub 2009 Feb 5.
79. JacquelineBarrett S., KimCanale E.K., RichardGearry B., PeterIrving M., PeterGibson R. Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J Gastroenterol 2008 August 28, 14(32):5020-5024.
80. Andriulli A., Neri M., Loguercio C., Terreni N., Merla A., Cardarella M.P., et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J Lin Gastroenterol 2008 Sep, 42(Suppl. 3 Pt 2):S218-S223.
81. Enck P., Zimmermann K., Menke G., Müller-Lissner S., Martens U., Klosterhalfen S. A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome-a randomized controlled trial with primary care physicians. Neurogastroenterol Motil 2008 Oct, 20(10):1103-1109. Epub 2008 Jun 28.
82. Drouault-Holowacz S., Bieuvelet S., Burckel A., Cazaubiel M., Dray X., Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2008 Feb, 32(2):147-152.
83. Sinn D.H., Song J.H., Kim H.J., Lee J.H., Son H.J., Chang D.K., et al. Therapeutic effect of lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008 Oct, 53(10):2714-2718. Epub 2008 Feb 15.
84. Bittner A.C., Croffut R.M., Stranahan M.C., Yokelson T.N. Prescript-assist™ probiotic-prebiotic treatment for irritable bowel syndrome: an open-label, partially controlled, 1-Year extension of a previously published controlled clinical trial. Clinical Therapeutics 2007, 29(6).
85. Guyonnet D., Chassany O., Ducrotte P., Picard C., Mouret M., Mercier C.H., et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007 Aug 1, 26(3):475-486.
86. Gawrońska A., Dziechciarz P., Horvath A., Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007 Jan 15, 25(2):177-184.
87. Fanigliulo L., Comparato G., Aragona G., Cavallaro L., Iori V., Maino M., et al. Role of gut microflora and probiotic effects in the irritable bowel syndrome. Acta Biomed 2006 Aug, 77(2):85-89.
88. Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O'Mahony L., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006 Jul, 101(7):1581-1590.
89. World Gastroenterology Organisation Global Guidelines. Inflammatory bowel disease: a global perspective. June 2009.
90. Furrie E., Macfarlane S., Kennedy A., Cummings J.H., Walsh S.V., O'neil D.A., et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005 Feb, 54(2):242-249.
91. Sokol Harry, Pigneur Bènèdicte, Watterlot Laurie, Lakhdari Omar, Bermùdez-Humaràn Luis G., Jean-Jacques Gratadoux, Blugeon Sèbastien, Bridonneau Chantal, Jean-Pierre Furet, Corthier Gèrard, Grangette Corinne, Vasquez Nadia, Pochart Philippe, Trugnan Germain, Thomas Ginette, Blottie re Hervè M., Dorè Joël, Marteau Philippe, Seksik Philippe, Langella Philippe Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008 Oct 28, 105(43):16731-16736.
92. Garcia Vilela Eduardo, De Lourdes De Abreu Ferrari Maria, Oswaldo Da Gama Torres Henrique, Guerra Pinto Ademar, Carolina Carneiro Aguirre Ana, Paiva Martins Fabiana, Marcos Andrade Goulart Eugenio, Sales Da Cunha Aloísio Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scandinavian Journal of Gastroenterology 2008, 43:842-848.
93. Fujimori Shunji, Tatsuguchi Atsushi, Gudis Katya, Kishida Teruyuki, Mitsui Keigo, Ehara Akihito, et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol 2007, 22:1199-1204.
94. Chermesh Irit, Tamir Ada, Reshef Ron, Chowers Yehuda, Suissa Alain, Katz Dalia, Gelber Moshe, Halpern Zamir, Bengmark Stig, Eliakim Rami Failure of synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig Dis Sci 2007, 52:385-389.
95. Van Gossum Andre, Dewit Olivier, Louis Edouard, de Hertogh Geert, Baert Filip, Fontaine PFernand, DeVos Martine, Enslen Marc, Paintin Marc, Franchimont Denis Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm Bowel Dis February 2007, 13(2).
96. Vasquez Nadia, Mangin Iréne, Lepage Patricia, Seksik Philippe, Duong Jean-Paul, Blum Stéphanie, et al. Patchy distribution of mucosal lesions in ileal Crohn's disease is not linked to differences in the dominant mucosa-associated bacteria: a study using fluorescence in situ hybridization and temporal temperature gradient gel electrophoresis. Inflamm Bowel Dis June 2007, 13(6).
97. Na Kim Mi, Kim Nayoung, Lee Sang Hyup, Soo Park Young, Hwang Jin-Hyeok, Kim Jin-Wook, Jeong Sook Hyang, Lee Dong Ho, Kim Joo Sung, Chae Jung Sung Song Hyun The effects of probiotics on PPI-Triple therapy for Helicobacter pylori eradication. Helicobacter 2008, 13:261-268.
98. Imase Kyoto, Takahashi Motomichi, Tanaka Akifumi, Tokunaga Kengo, Sugano Hajime, Tanaka Mamoru, Ishida Hitoshi, Kamiya Shigeru, Takahashi Shin'ichi Efficacy of clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota. Microbiol Immunol 2008, 52:156-161.
99. Ruggiero Francavilla, Elena Lionetti, Stefania Paola Castellaneta, Anna Maria Magistà, Giovanni Maurogiovanni, Nunzia Bucci, et al, Vito Leonardo Miniello. Inhibition of Helicobacter pylori infection in humans by lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter 13: 127-134.
100. Cindoruk Mehmet, Erkan Gulbanu, Karakan Tarkan, Dursun Ayse, Unal Selahattin Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007, 12:309-316.
101. Scaccianoce G., Zullo A., Hassan C., Gentili F., Cristofari F., Cardinale V., et al. Triple therapy plus different probiotics for Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci 2008, 12:251-256.
102. Kazuyoshi Takeda, Ko Okumura. Effects of a fermented milk drink containing lactobacillus casei strain Shirota on the human NK-Cell activity. J Nutr.
103. Hatakka Katja, Holma Reetta, El-Nezami Hani, Suomalainen Tarja, Kuisma Minna, Saxelin Maija, Poussa Tuija, Mykkänen Hannu, Korpela Riitta The influence of lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp. shermanii JS on potentially carcinogenic bacterial activity in human colon. Int J Food Microbiol 2008, 128:406-410.
104. Roller Monika, Clune Yvonne, Collins Kevin, Rechkemmer Gerhard, Watzl Bernhard Consumption of prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis has minor effects on selected immune parameters in polypectomised and colon cancer patients. Br J Nutr 2007, 97:676-684.
105. Rafter Joseph, Bennett Michael, Caderni Giovanna, Clune Yvonne, Hughes Roisin, Karlsson Pernilla C., Klinder Annett, O'Riordan Micheal, O'Sullivan Gerald C., Pool-Zobel Beatrice, Rechkemmer Gerhard, Roller Monika, Rowland Ian, Salvadori Maddalena, Thijs Herbert, Van Loo Jan, Watzl Bernhard, Collins John K. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr 2007, 85:488-496.
106. Saavedra Jose Probiotics and infectious diarrhea. Am J Gastroenterol 2000, 95(No 1, Suppl.).
107. Rendi-Wagner Pamela, Kollaritsch Herwig Drug prophylaxis for traveleres' diarrhea. CID 2002, 34. (1 March).
108. Dubey A.P., Rajeshwari K., Chakravarty A., Famularo G. Use of VSL[sharp]3 in the treatment of rotavirus diarrhea in children: preliminary results. J Clin Gastroenterol 2008 Sep, 42(Suppl. 3 Pt 1):S126-S129.
109. Narayanappa D. Randomized double blinded controlled trial to evaluate the efficacy and safety of Bifilac in patients with acute viral diarrhea. Indian J Pediatr 2008 Jul, 75(7):709-713. Epub 2008 Aug 21.
110. Henker J., Laass M., Blokhin B.M., Bolbot Y.K., Maydannik V.G., Elze M., et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr 2007 Apr, 166(4):311-318. Epub 2007 Feb 8.
111. Basu S., Chatterjee M., Ganguly S., Chandra P.K. Efficacy of Lactobacillus rhamnosus GG in acute watery diarrhoea of Indian children: a randomised controlled trial. J Paediatr Child Health 2007 Dec, 43(12):837-842. Epub 2007 Sep 4.
112. Szymański H., Armańska M., Kowalska-Duplaga K., Szajewska H. Bifidobacterium longum PL03, Lactobacillus rhamnosus KL53A, and Lactobacillus plantarum PL02 in the prevention of antibiotic-associated diarrhea in children: a randomized controlled pilot trial. Digestion 2008, 78(1):13-17. Epub 2008 Aug 14.
113. Ruszczyński M., Radzikowski A., Szajewska H. Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment Pharmacol Ther 2008 Jul, 28(1):154-161. Epub 2008 Apr 13.
114. Beausoleil M., Fortier N., Guénette S., L'ecuyer A., Savoie M., Franco M., et al. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol 2007 Nov, 21(11):732-736.
115. Hickson M., D'Souza A.L., Muthu N., Rogers T.R., Want S., Rajkumar C., et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007 Jul 14, 335(7610):80. Epub 2007 Jun 29.
116. Wenus C., Goll R., Loken E.B., Biong A.S., Halvorsen D.S., Florholmen J. Prevention of antibiotic-associated diarrhoea by a fermented probiotic milk drink. Eur J Clin Nutr 2008 Feb, 62(2):299-301. Epub 2007 Mar 14.
117. Koning C.J., Jonkers D.M., Stobberingh E.E., Mulder L., Rombouts F.M., Stockbrügger R.W. The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin. Am J Gastroenterol 2008 Jan, 103(1):178-189. Epub 2007 Sep 25.
118. Sabia Carla, Niederhausern Simona de, Guerrieri Elisa, Bondi Moreno, Anacarso Immacolata, Iseppi Ramona, Messi Patrizia Interference of lactobacillus plantarum strains in the in vitro conjugative transfer of R-plasmids. Curr Microbiol 2009 Feb, 58(2):101-105. Epub 2008 Sep 23.
119. Hoesl C.E., Altwein J.E. The probiotic approach: an alternative treatment option urology. Eur Urol 2005, 47:288-296.
120. Hoppe B., Beck B., Gatter N., von Unruh G., Tischer A., Hesse A., et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 2006 Oct, 70(7):1305-1311. Epub 2006 Jul 19.
121. Skovbjerg S., Roos K., Holm S.E., Grahn Hakansson E., Nowrouzian F., Ivarsson M., et al. Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. Arch Dis Child 2009 Feb, 94(2):92-98. Epub 2008 Aug 19.
122. Sherman Philip M., FRCPC, Ossa Juan C., Johnson-Henry Kathene Unraveling mechanisms of action of probiotics. Nutr Clin Pract February/March 2009, 24(No. 1).